AXL expression to predict resistance to immunotherapy in metastatic non-small cell lung cancer
{{output}}
Background: Non-small cell lung cancer (NSCLC) remains a major therapeutic challenge. While PD-1/PD-L1 immunotherapies have improved outcomes, predictive biomarkers are limited. AXL, a receptor tyrosine kinase associated with poo... ...
